{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=28&state=Georgia",
    "query": {
      "state": "Georgia",
      "city": "Atlanta",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 13066,
    "total_pages": 1307,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=29&state=Georgia&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=27&state=Georgia&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T15:54:48.586Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05683379",
      "title": "AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "AAV8 DetectCDx",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "25 Years",
        "sex": "MALE",
        "summary": "0 Years to 25 Years · Male only"
      },
      "enrollment_count": 200,
      "start_date": "2022-12-20",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05683379"
    },
    {
      "nct_id": "NCT03371108",
      "title": "Gan & Lee Insulin Glargine Target Type (2) Evaluating Research",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Gan & Lee Insulin Glargine Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lantus®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gan and Lee Pharmaceuticals, USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 567,
      "start_date": "2017-10-31",
      "completion_date": "2019-04-17",
      "has_results": true,
      "last_update_posted_date": "2022-04-01",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03371108"
    },
    {
      "nct_id": "NCT00041925",
      "title": "Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Peripheral Vascular Diseases",
        "Arterial Occlusive Diseases",
        "Ischemia",
        "Graft Occlusion, Vascular",
        "Hyperplasia"
      ],
      "interventions": [
        {
          "name": "CGT003 (E2F Duplex Decoy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anesiva, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1400,
      "start_date": "2001-11",
      "completion_date": "2004-11",
      "has_results": false,
      "last_update_posted_date": "2005-07-15",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 116,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00041925"
    },
    {
      "nct_id": "NCT00102518",
      "title": "Aripiprazole Open-Label, Safety and Tolerability Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 325,
      "start_date": "2004-09",
      "completion_date": "2007-02",
      "has_results": true,
      "last_update_posted_date": "2012-08-31",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00102518"
    },
    {
      "nct_id": "NCT05997290",
      "title": "A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2 Infection",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "BNT162b2 (Omi XBB.1.5)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (Omi JN.1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (Omi KP.2)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1051,
      "start_date": "2023-08-10",
      "completion_date": "2025-03-13",
      "has_results": true,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 37,
      "location_summary": "Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05997290"
    },
    {
      "nct_id": "NCT02411110",
      "title": "A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystitis, Interstitial",
        "Painful Bladder Syndrome"
      ],
      "interventions": [
        {
          "name": "LiRIS®",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "LiRIS Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 131,
      "start_date": "2015-05-21",
      "completion_date": "2017-01-09",
      "has_results": true,
      "last_update_posted_date": "2018-01-04",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 31,
      "location_summary": "Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02411110"
    },
    {
      "nct_id": "NCT00006024",
      "title": "Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Tumor",
        "Central Nervous System Tumor"
      ],
      "interventions": [
        {
          "name": "lomustine",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 32,
      "start_date": "2000-11",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2014-02-13",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 206,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006024"
    },
    {
      "nct_id": "NCT04987762",
      "title": "Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Adhansia XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Purdue Pharma LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 103,
      "start_date": "2021-08-03",
      "completion_date": "2022-04-27",
      "has_results": true,
      "last_update_posted_date": "2023-08-22",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 15,
      "location_summary": "Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lauderhill",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04987762"
    },
    {
      "nct_id": "NCT02687035",
      "title": "PARTNER II Trial: S3iCAP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aortic Stenosis"
      ],
      "interventions": [
        {
          "name": "SAPIEN S3 valve",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Edwards Lifesciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1822,
      "start_date": "2015-01",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 55,
      "location_summary": "La Jolla, California • Los Angeles, California • Palo Alto, California + 46 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02687035"
    },
    {
      "nct_id": "NCT01272635",
      "title": "Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma",
        "Wheezing"
      ],
      "interventions": [
        {
          "name": "Azithromycin",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo Azithromycin",
          "type": "OTHER"
        },
        {
          "name": "Placebo Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "71 Months",
        "sex": "ALL",
        "summary": "12 Months to 71 Months"
      },
      "enrollment_count": 607,
      "start_date": "2011-03",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-12-28",
      "last_synced_at": "2026-11-07T15:54:48.586Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Oakland, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272635"
    }
  ]
}